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Invasive micropapillary carcinoma of the
breast had poor clinical characteristics but
showed no difference in prognosis
compared with invasive ductal carcinoma
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Abstract
Background: It is controversial for prognosis of invasive micropapillary carcinoma (IMPC) compared with invasive
ductal carcinoma (IDC) of the breast. To better understand the difference between IMPC and IDC prognoses, we
conducted this retrospective study.
Methods: Data from 33 patients with IMPC were retrospectively reviewed, and the clinicopathologic characteristics
and survival status were compared with those of 347 patients with IDC who were treated during the same period.
Results: The IMPC cases were of larger tumor size, greater proportion of nodal involvement, and an increased
incidence of lymphovascular invasion compared with IDC cases. The overall survival (OS), local relapse-free survival
(LRFS), distant metastasis-free survival (DMFS), and failure-free survival (FFS) rates were not significantly different
between IMPC and IDC. The 3-year OS rate was 97 vs 94.2 % for the IMPC and IDC patients, respectively. The 3-year FFS
rate was 87.9 vs 86.2 % for the IMPC and IDC patients, respectively. For IMPC patients, the 3-year LRFS rate was 93.9 %
and in IDC patients was 89.0 %. The 3-year DMFS rates of IMPC patients was 90.9 % and IDC patients was 89 %.
Conclusions: IMPC had poor clinical characteristics, but it showed no difference in OS, FFS, LRFS, and DMFS
compare with IDC.
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Background
Breast cancer now represents the most common female
malignancy in both the developing and developed world,
and is the primary cause of death among women
globally [1]. Invasive micropapillary carcinoma (IMPC)
was first described by Siriaunkgul and Tavassoli as a rare
variant of invasive breast carcinoma characterized by
pseudopapillary and tubuloalveolar arrangement of tumor
cell clusters in sponge-like, clear empty spaces, mimicking
extensive lymphatic invasion [2].
As described by Luna More et al., IMPC is character-
ized by small, tightly cohesive groups of neoplastic cells
within well-delineated clear spaces resembling lymphatic
vessels [3].
The incidence of IMPC ranges from 3 to 6 % of all
primary breast cancers [4]. Due to the low incidence of
this breast cancer variant, most studies examining IMPC
have small sample sizes; the clinicopathological character-
istics and the clinical prognostic factors of invasive micro-
papillary carcinoma are therefore not well understood.
It is an important subtype due to its unique features
such as high proclivity to lymphovascular invasion,
lymph node metastasis, local recurrence, and distant
metastasis, thus exhibiting a more aggressive behavior
with a poorer prognosis than invasive ductal carcinoma
(IDC) [4–8]. However, recently, it has been reported that
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this carcinoma IMPC has a similar or favorable progno-
sis compared with IDC [9, 10].
There is controversy about the prognosis of IMPC of
the breast. Therefore, greater understanding about these
rare tumors is urgent. The aims of this study were to
investigate the clinicopathologic characteristics, treatment
patterns, and the clinical outcomes compared with IDC in
Hainan Island of South China. Moreover, the objective of
this article is to draw attention to summarizing the
survival rate of IMPC compared with IDC among the
similar literatures.
Methods
We conducted a retrospective study of breast cancer
patients who were treated at the Hainan Province
People’s Hospital between January 2010 and December
2012. This study was approved by the institutional review
board and ethics committee of our hospital. In these
periods, a total of 525 patients had operations for breast
cancers in this institute. Of them, 33 patients (6.3 %) were
diagnosed with IMPC (including pure and mixed type)
and 347 patients were diagnosed with pure IDC. All IMPC
cases included in the study displayed a micropapillary
tumor component that was in accordance with the mor-
phological criteria described in the WHO histological clas-
sification of tumors of the breast [11]. These patients were
compared with 347 patients with pure IDC who were
treated during the same period. Of the 33 IMPC cases, 16
patients (48.5 %) were identified as having pure IMPC,
whereas 17 patients (51.5 %) had mixed IMPC. We
reviewed clinicopathologic factors, immunohistochemis-
tries of biologic factors such as estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth
factor receptor 2 (HER2), and treatment modalities
(type of operation, use of chemotherapy, radiation ther-
apy, and hormone therapy). The pathologic tumor stage
was assessed according to the sixth American Joint Com-
mittee on Cancer (AJCC) staging system [12]. All patients
were followed up by our department at 3-month intervals
for the first 2 years, every 6 months for 3–5 years, and an-
nually thereafter. All events were measured from the date
of commencement of operation. The following end points
(time to the first defining event) were assessed: overall sur-
vival (OS), failure-free survival (FFS), local relapse-free sur-
vival (LRFS), and distant metastasis-free survival (DMFS).
Statistical analysis
The clinicopathological parameters of the different sub-
groups were compared using Pearson’s chi-square test;
Fisher’s exact test was used when needed. Survival
curves were determined and plotted using the Kaplan-
Meier method and group differences in survival time
were investigated by log-rank test. P values less than
0.05 was considered statistically significant. Hazard
ratios (HR) were presented with 95 % confidence intervals.
SPSS for Windows (version 16.0, SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses.
Results
The clinicopathological characteristics of patients with
IMPC and IDC
A total of 33 patients with IMPC of the breast were identi-
fied in our database. At the same time, 347 patients with
IDC were also identified. The clinico-pathologic charac-
teristics of all patients are summarized in Table 1.
When comparing staging at presentation, IMPC pa-
tients had more T3 or T4 tumors (P = 0.044), a higher
percentage of N1-3 nodal involvement (P < 0.001). IMPC
patients had a higher incidence of lymphovascular inva-
sion (P < 0.001) and nerve invasion (P = 0.007) compared
with IDC patients.
Furthermore, IMPC patients had a larger proportion
with luminal subtype than IDC patients (P = 0.006).
Expressions of ER were significantly higher (P = 0.011),
and expressions of PR were slight higher (P = 0.123) in
IMPC than in IDC. Expressions of Her2 were not statis-
tically significantly different in the IMPC and IDC cases.
Hormone therapy was significantly higher in IMPC
patients. Chemotherapy and radiotherapy were slightly
higher in the IMPC group but not statistically signifi-
cant. In addition, there were no significant differences in
age, family history, and Her2 status.
Survival of patients with IMPC and IDC
The median follow-up duration was 39 months for all
patients (range 6 to 66). The OS, FFS, LRFS, and
DMFS rates were not significantly different between
IMPC and IDC. The 3-year OS rate was 97 vs 94.2 %
for the IMPC and IDC patients, respectively (P = 0.78)
(Fig. 1a). The 3-year FFS rate was 87.9 vs 86.2 % for the
IMPC and IDC patients, respectively (P = 0.88) (Fig. 1b).
For IMPC patients, the 3-year LRFS rate was 93.9 %, and in
IDC patients, it was 89.0 % (P = 0.88) (Fig. 1c). The 3-year
DMFS rates of IMPC patients was 90.9 % and IDC patients
was 89.0 % (P = 0.97) (Fig. 1d).
Failure pattern
The 55 patients with treatment failure are listed in
Table 2. The IMPC group had four patients that devel-
oped treatment failure: there was relapsing event in one
patient, distant metastatic event in two patients (both of
them had developed multi-organ metastasis), and both
distant metastasis and recurrence in one patient.
In IDC group, 51 patients in all had developed treat-
ment failure: there was relapsing event in 11 patients,
distant metastatic event in 26 patients and 14 patients had
both distant metastasis and recurrence. Seventeen patients
had developed distant metastasis in a single organ: ten
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cases in bone, five cases in lung, and two cases in liver.
Nine patients had developed multi-organ metastasis.
Discussion
IMPC is a rare pathological subtype of breast cancer, and
the pure variant of IMPC is even rarer. Previous studies
have shown that most patients (80~86 %) had mixed
IMPC [7, 13]. In our study, most patients (57.6 %) had
pure IMPC, whereas only 42.4 % had the mixed form.
Previous studies have shown that IMPC usually presents
with a higher TNM stage and is associated with lympho-
vascular invasion and a higher propensity for lymph node
metastases [4–8]. In our study, IMPC patients had more
T3 or T4 tumors, a higher percentage of N1–N3 nodal
involvement, and a higher incidence of lymphovascular
invasion and nerve invasion compared with IDC patients,
which is consistent with previous reports.
Most studies reported higher rate of ER positivity than
the IDC comparison group (Table 3), and only two
studies showed lower or similar rate of ER positivity
(Table 3). In our study, the high percentages of ER and
PR positivity in IMPCs (81.8 and 75.8 %, respectively)
are in accordance with other reports [13–15]. Recently,
Rodrigues’ study demonstrated the nuclear localization
of epidermal growth factor receptor (EGFR) in the canine
spontaneous model of IMPC of the mammary gland. This
finding could be useful for EGFR as a predictive biomarker
of therapeutic response for IMPC [16].
There were no prospective study and only seven
studies for comparative analysis between IMPC and IDC
Table 1 Baseline characteristics and treatment patterns for
IMPC and IDC
IMPC (n = 33) IDC (n = 347) P*
Age (year) 0.885
≤45 11 (33.3 %) 120 (34.6 %)
>45 22 (66.7 %) 227 (65.4 %)
Family history 0.179
Yes 2 (6.1 %) 7 (2.0 %)
No 17 (21.5 %) 340 (98.0 %)
ER status 0.011
Positive 27 (81.8 %) 206 (59.4 %)
Negative 6 (18.2 %) 141 (40.6 %)
PR status 0.123
Positive 25 (75.8 %) 209 (62.6 %)
Negative 8 (24.2 %) 125 (37.4 %)
Her2 status 0.479
Positive 6 (18.8 %) 82 (24.3 %)
Negative 26 (81.2 %) 255 (75.7 %)
Unknown 1 10
Subtype 0.006
Luminal 29 (87.9 %) 223 (64.3 %)
Non-luminal 4 (12.1 %) 124 (35.7 %)
T classification 0.044
T1–T2 25 (75.8 %) 309 (89.0 %)
T3–T4 8 (24.2 %) 38 (11.0 %)
N classification <0.001
N0 7 (21.2 %) 186 (53.8 %)
N1–N3 26 (78.2 %) 160 (46.2 %)
Unknown 0 1
Staging <0.001
I–II 15 (45.5 %) 262 (76.2 %)
III 18 (54.5 %) 82 (23.8 %)
Unknown 0 3
Operation methods 0.392
BCS 0 (0 %) 19 (5.5 %)
Mastectomy 33 (100 %) 328 (94.5 %)
Adjuvant chemotherapy 0.709
Yes 32 (97 %) 321 (93.3 %)
No 1 (3.0 %) 23 (6.7 %)
Unknown 0 3
Radiotherapy 0.146
Yes 14 (42.4 %) 104 (30.1 %)
No 19 (57.6 %) 241 (69.9 %)
Unknown 0 2
Table 1 Baseline characteristics and treatment patterns for
IMPC and IDC (Continued)
Hormone therapy 0.026
Yes 28 (84.8 %) 227 (65.8 %)
No 5 (15.2 %) 118 (34.2 %)
Unknown 0 2
Neoadjuvant chemotherapy 0.128
Yes 4 (12.1 %) 19 (5.5 %)
No 29 (87.9 %) 328 (94.5 %)
Trastuzumab 0.754
Yes 2 (6.1 %) 33 (9.5 %)
No 31 (93.9 %) 314 (90.5 %)
Lymphovascular invasion <0.001
Yes 6 (18.2 %) 2 (0.6 %)
No 27 (81.8 %) 345 (99.4 %)
Nerve invasion 0.007
Yes 2 (6.1 %) 0 (0 %)
No 3193.9 %) 347 (100 %)
IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma,
ER estrogen receptor, PR progesterone receptor
* All P values calculated by two-sided x2 test
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in nearly 20 years, but the criteria of eligible patients were
diverse (Table 3). For example, the criteria of eligible pa-
tients in Chen’s report was “randomly selected,” the
criteria of eligible patients in Yu’s report was “age, patho-
logic tumor and node stage, treatment method,” and so
on. The criteria of eligible patients in Chen’s report was
“the same study period” which was the same as our study.
It is widely agreed IMPC has its unique features such
as high proclivity to lymphovascular invasion (LVI) and
axillary lymph node (ALN) metastasis [7–10, 14]. How-
ever, it is controversial for survival rate of IMPC com-
pared with IDC (Table 4).
In 2008, Chen [4] reported that the survival at 5 and
10 years in the IMPC group was significantly lower than
the survival rates in the IDC group. In 2010, Yu [8]
showed that the locoregional recurrence-free survival at
5 years in IMPC patients was significantly lower than that
in IDC patients, but the 5-year OS and DMFS was no
different between two groups. Vingiani [14] reported that
disease-free survival (DFS) and OS from breast cancer for
Table 2 Patterns of failure in the IMPC and IDC patients
after treatment




Recurrence n (%) n (%)
Primary recurrence 1 (3 %) 9(2.6 %)
Nodal recurrence 0 (0 %) 2 (0.6 %)
Distant metastasis n (%) n (%)
Bone metastasis 0 (0 %) 10 (2.9 %)
Lung metastasis 0 (0 %) 5 (1.4 %)
Liver metastasis 0 (0 %) 2 (0.6 %)
Mediastina metastasis 0 (0 %) 0 (0.0 %)
Multiple metastasis 2 (6.1 %) 9 (2.6 %)
Distant metastasis, primary
and/or nodal recurrence
1 (3 %) 14 (4 %)
IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma
Fig. 1 Kaplan-Meier survival curves for 33 patients with IMPC and 347 patients with IDC. Overall survival (a), failure-free survival (b), local relapse-free
survival (c), and distant metastasis-free survival (d). P values were calculated with the unadjusted log-rank test. IMPC invasive micropapillary carcinoma,
IDC invasive ductal carcinoma
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MPC and IDC patients were not statistically different in
2013. However, Vingiani’s report did not compare with
Chen’s report. Vingiani’s report also did not analyze the
detail between their study and Yu’s study.
In 2014, three larger retrospective studies have been
reported. Liu et al. [9] showed that no difference in DFS
was observed between IMPC and LN-matched IDC
patients, but IMPC patients demonstrated significantly
reduced survival compared to IDC patients in the
T1N2–3 subpopulation, whereas IDC patients demon-
strated significantly increased recurrence and metastasis
compared to IMPC patients in the T2N2–3 subgroup.
Chen et al. [10] showed that despite IMPC’s higher pro-
pensity for lymph node metastasis, IMPC has disease-
specific survival (DSS) and overall survival (OS) that
compare favorably with IDC (the 5-year rates comparing
DSS and OS for IMPC was 91.8 and 82.9 %, respectively,
compared with 88.6 and 80.5 % for IDC, respectively).
However, Shi’s [7] results were different from Liu’s and
Chen’s. Shi’s report revealed that patients with IMPC
had poorer 5-year BCSS and RFS rates (75.9 and 67.1 %,
respectively) than patients with IDC (89.5 %, P = 0.001
and 84.5 %, P < 0.001, respectively).
Recently, a retrospective multicenter study by Yu et al.
[17] showed that the rate of distant metastasis (P = 0.52)
and overall survival (P = 0.67) did not differ between the
two groups. However, LRR-free survival (P = 0.03) and
recurrence-free survival (P = 0.007) were significantly
different between the two groups. These results were in
line with their previous results in 2010 [8].
In brief, six of seven studies referred to the OS, and
four of the six studies suggested that the OS of IMPC is
not inferior to that of IDC. Just scattered studies
provided information about RFS and DMS in the IMPC
and matched series of IDC patients. Only Yu’s and
Chen’s studies mentioned RFS and DMS; they revealed
Table 3 Characteristics on breast IMPC and IDC in previous seven reports and the present study
Author Published
time










Chen [4] 2008 100 100 Mixed Randomly selected Lower Lower \
Yu [8] 2010 72 144 Pure or more
than 70 %
Age, pathologic tumor and
node stage, treatment methods
Higher Higher Higher
Vingiani [14] 2013 49 98 Pure Age, tumor size and grade Higher Higher Higher
Liu [9] 2014 51 102 Pure Nodal status and age Higher Higher Higher
Shi [7] 2014 188 1289 mixed Simple random sampling Higher Higher Higher
Chen [10] 2014 636 297735 unknown The same study period Higher Higher \
Yu [16] 2015 267 267 Mixed Age, pathologic tumor and
node stage, treatment method
Similar Similar Higher
Present study \ 33 347 Mixed The same study period Higher Higher Higher
NO number, IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma, ER estrogen receptor, PR progesterone receptor
Table 4 Survival on breast IMPC and IDC in previous seven reports and the present study
Author Median follow-up (month) OS (IMPC vs IDC) FFS (IMPC vs IDC) LRFS (IMPC vs IDC) DMFS (IMPC vs IDC)
Chen [4] 60.1 59 vs 77 %
P = 0.004
/ 88.8 vs 96 %
P = 0.055
61.2 vs 72 %
P = 0.108
Yu [8] 45.0 86 vs 87.7 %
P = 0.18
/ 68.2 vs 81.4 %
P = 0.045
78.1 vs 79.3 %
P = 0.86
Vingiani [14] 51.0 89.8 vs 90.8 %
P = 0.8
75.5 vs 79.6 %
P = 0.47
/ /
Liu [9] 68.4 / 84.3 vs 78.4 %
P = 0.518
/ /
Shi [7] 40.5 75.9 vs 89.5 %
P = 0.001
67.1 vs 84.5 %
P < 0.001
/ /
Chen [10] 48.0 82.9 vs 80.5 %
P = 0.52
/ / /
Yu [16] 59.0 97.7 vs 95.7 %
P = 0.67
/ 91.8 vs 96.3 %
P = 0.03
/
Present study 39.0 97 vs 94.2 %
P = 0.78
87.9 vs 86.2 %
P = 0.91
93.9 vs 89.0 %
P = 0.82
90.9 vs 89 %
P = 0.97
IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival,
FFS failure-free survival
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that IMPC showed a tendency for a higher recurrence rate
and had a risk of distant metastasis similar to that
observed in the matched series of IDC patients. In our
study, IMPC has FFS and OS that compare similarly with
IDC which is consistent with Chen’s study. However,
Chen’s study did not provided information about LRFS
and DMFS. We also analyzed the failure pattern and
found that IMPC has LRFS and DMFS that compare
similarly with IDC.
Nodal status, tumor size, tumor characteristics, and
choice of surgery will dictate additional adjuvant
therapies like chemotherapy, radiation, and hormonal
therapy [18]. Patients with IMPC who had high per-
centages of ER and PR positivity, larger tumor size,
greater proportion of nodal involvement, and an increased
incidence of lymphovascular invasion showed no difference
in survival. We thought maybe it is largely attributable to
getting much more endocrine therapy, adjuvant chemo-
therapy, and radiotherapy than those with IDC. There are
some limitations in this study. First, the number of IMPC
patients was small. Second, the retrospective nature of the
data introduces bias. Third, Ki-67 pathological data were
not routinely obtained from patients, while Ki-67 was
commonly used as a prognostic factor. In addition, longer
follow-up is needed to verify the prognosis of IMPC
in our study.
We believe that there will be more large-scale retro-
spective studies or clinical trials about IMPC of the
breast to understand the prognosis. Why did the IMPC
show no difference in prognosis compared with IDC
though it had inferior clinical characteristics? Is it largely
attributable to getting much more endocrine therapy,
adjuvant chemotherapy, and radiotherapy than those
with IDC? Or did IMPC have unique features of the
molecular mechanisms that underlie its pathology and
progression? These issues deserve our further study.
Conclusions
Patients with IMPC had high percentages of ER and PR
positivity, larger tumor size, greater proportion of nodal
involvement, and an increased incidence of lymphovas-
cular invasion. IMPC showed no difference in OS, FFS,
LRFS, and DMFS compare with IDC.
Abbreviations
DMFS, distant metastasis-free survival; ER, estrogen receptor; FFS, failure-free
survival; IDC, invasive ductal carcinoma; IMPC, invasive micropapillary carcinoma;
LRFS, local relapse-free survival; OS, overall survival; PR, progesterone receptor
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